

# Quang-De Nguyen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6723004/publications.pdf>

Version: 2024-02-01

59  
papers

4,899  
citations

126858

33  
h-index

138417

58  
g-index

60  
all docs

60  
docs citations

60  
times ranked

8662  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-CAIX BBÎ¶ CAR4/8 TÂcells exhibit superior efficacy in a ccRCC mouse model. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 385-399.	2.0	15
2	Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. <i>Cancer Research</i> , 2022, 82, 248-263.	0.4	17
3	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 276-287.	3.2	100
4	DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i12-i13.	0.4	1
5	FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance. <i>Nature Cell Biology</i> , 2021, 23, 1187-1198.	4.6	21
6	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. <i>Molecular Cell</i> , 2020, 78, 1096-1113.e8.	4.5	114
7	IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii106-ii106.	0.6	1
8	TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENE. <i>Neuro-Oncology</i> , 2020, 22, ii230-ii231.	0.6	1
9	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	13.5	1,408
10	Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. <i>Cancer Cell</i> , 2019, 36, 528-544.e10.	7.7	128
11	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. <i>Genes and Development</i> , 2019, 33, 1718-1738.	2.7	65
12	Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. <i>Nature Communications</i> , 2019, 10, 4182.	5.8	37
13	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. <i>Cancer Discovery</i> , 2019, 9, 944-961.	7.7	36
14	Development and Evaluation of an <sup>18</sup> F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression. <i>Molecular Pharmaceutics</i> , 2019, 16, 2106-2117.	2.3	26
15	Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma. <i>Nanoscale</i> , 2019, 11, 20485-20496.	2.8	27
16	Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. <i>Cancer Discovery</i> , 2019, 9, 230-247.	7.7	119
17	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. <i>Cancer Immunology Research</i> , 2018, 6, 389-401.	1.6	68
18	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	6.0	461

#	ARTICLE	IF	CITATIONS
19	Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3741-E3748.	3.3	10
20	Development and validation of a new MRI simulation technique that can reliably estimate optimal in vivo scanning parameters in a glioblastoma murine model. <i>PLoS ONE</i> , 2018, 13, e0200611.	1.1	4
21	Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using <sup>18</sup> F-ICMT-11 and <sup>18</sup> F-FLT PET. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1558-1565.	2.8	8
22	Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C. <i>Journal of Clinical Investigation</i> , 2017, 127, 4554-4568.	3.9	21
23	Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography. <i>PLoS ONE</i> , 2016, 11, e0161427.	1.1	2
24	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016, 22, 723-726.	15.2	105
25	Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. <i>Journal of the American College of Radiology</i> , 2016, 13, 365-371.	0.9	12
26	ImmunopET compared with conventional imaging modalities for the detection of Ewing sarcoma metastases in a preclinical model.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10048-10048.	0.8	0
27	Positron Emission Tomography Imaging with <sup>18</sup> F-Labeled Z <sup>HER2:2891</sup> Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies. <i>Clinical Cancer Research</i> , 2014, 20, 1632-1643.	3.2	32
28	Synthesis of a new fluorine- <sup>18</sup> glycosylated "click" cyanoquinoline for the imaging of epidermal growth factor receptor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 92-96.	0.5	8
29	A Novel Radiotracer to Image Glycogen Metabolism in Tumors by Positron Emission Tomography. <i>Cancer Research</i> , 2014, 74, 1319-1328.	0.4	38
30	Anti-nicestrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 455-462.	1.1	22
31	Preclinical evaluation of a CXCR4-specific <sup>68</sup> Ga-labelled TN14003 derivative for cancer PET imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 796-803.	1.4	22
32	Preclinical Evaluation of <sup>18</sup> F-Fluoro-2,2-Dimethylpropionic Acid as an Imaging Agent for Tumor Detection. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1506-1512.	2.8	22
33	CXCR4-Targeted and MMP-Responsive Iron Oxide Nanoparticles for Enhanced Magnetic Resonance Imaging. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 9550-9554.	7.2	146
34	Phosphorylation Status of Thymidine Kinase 1 Following Antiproliferative Drug Treatment Mediates <sup>3</sup> -Deoxy- <sup>3</sup> -[ <sup>18</sup> F]-Fluorothymidine Cellular Retention. <i>PLoS ONE</i> , 2014, 9, e101366.	1.1	4
35	Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3 Selective Molecular Imaging. <i>Clinical Cancer Research</i> , 2013, 19, 3914-3924.	3.2	48
36	Heterogeneity in Lung <sup>18</sup> F FDG Uptake in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 1214-1224.	1.6	107

#	ARTICLE	IF	CITATIONS
37	Scavenging strategy for specific activity improvement: application to a new CXCR4-specific cyclopentapeptide positron emission tomography tracer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 679-685.	0.5	9
38	Evaluation of Deuterated 18F- and 11C-Labeled Choline Analogs for Cancer Detection by Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2012, 18, 1063-1072.	3.2	58
39	Synthesis and evaluation of nucleoside radiotracers for imaging proliferation. <i>Nuclear Medicine and Biology</i> , 2012, 39, 652-665.	0.3	16
40	18F-labelling of a cyclic pentapeptide inhibitor of the chemokine receptor CXCR4. <i>Journal of Fluorine Chemistry</i> , 2012, 135, 200-206.	0.9	12
41	Glucose Metabolism Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells. <i>Translational Oncology</i> , 2011, 4, 241-248.	1.7	21
42	Radiosynthesis and pre-clinical evaluation of [18F]fluoro-[1,2-2H4]choline. <i>Nuclear Medicine and Biology</i> , 2011, 38, 39-51.	0.3	37
43	Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: Synthesis and biological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6634-6645.	1.4	49
44	[18F]Fluoromethyl-[1,2-2H4]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography. <i>Cancer Research</i> , 2009, 69, 7721-7728.	0.4	37
45	Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [ <sup>18</sup> F]-labeled isatin sulfonamide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16375-16380.	3.3	157
46	Design, Synthesis, and Biological Characterization of a Caspase 3/7 Selective Isatin Labeled with 2-[ <sup>18</sup> F]fluoroethylazide. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 8057-8067.	2.9	126
47	Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3112-3121.	1.9	43
48	Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3147-3157.	1.9	65
49	Anticancer Activity of BIM-46174, a New Inhibitor of the Heterotrimeric G $\alpha$ /G $\beta$ $\gamma$ Protein Complex. <i>Cancer Research</i> , 2006, 66, 9227-9234.	0.4	57
50	Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2070-2077.	1.9	41
51	Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. <i>Oncogene</i> , 2005, 24, 8240-8251.	2.6	47
52	Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac. <i>FASEB Journal</i> , 2004, 18, 1016-1018.	0.2	348
53	Nuclear bodies and compartments: functional roles and cellular signalling in health and disease. <i>Cellular Signalling</i> , 2004, 16, 1085-1104.	1.7	141
54	Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells. <i>Oncogene</i> , 2003, 22, 4488-4497.	2.6	53

#	ARTICLE	IF	CITATIONS
55	Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase $\alpha$ 2 and EGF receptor signaling. <i>FASEB Journal</i> , 2003, 17, 7-16.	0.2	117
56	RhoA $\alpha$ and RhoD $\alpha$ dependent regulatory switch of G $\beta$ subunit signaling by PAR $\alpha$ 1 receptors in cellular invasion. <i>FASEB Journal</i> , 2002, 16, 565-576.	0.2	56
57	G-protein $\beta$ subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. <i>Oncogene</i> , 2002, 21, 4020-4031.	2.6	40
58	Suppression of Cellular Invasion by Activated G-Protein Subunits G $\beta$ o, G $\beta$ i1, G $\beta$ i2, and G $\beta$ i3 and Sequestration of G $\beta$ i3. <i>Molecular Pharmacology</i> , 2001, 60, 363-372.	1.0	41
59	Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase $\alpha$ and thromboxane A2 receptor $\alpha$ dependent signaling pathways. <i>FASEB Journal</i> , 2001, 15, 1517-1528.	0.2	72